These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 5475414)

  • 41. Early hospital experience with fluphenazine decanoate.
    Small JG; Kellams J
    Dis Nerv Syst; 1974 Oct; 35(10):453-6. PubMed ID: 17894058
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective.
    Dencker SJ
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):22-7. PubMed ID: 6143744
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Clinical therapeutic experiences with fluphenazine].
    Pfeiffer WM
    Arzneimittelforschung; 1967 Oct; 17(10):1327-9. PubMed ID: 5632888
    [No Abstract]   [Full Text] [Related]  

  • 45. [Treatment of schizophrenic psychoses by sustained-action neuroleptics in psychiatric outpatients' treatment (author's transl)].
    Polácek J
    Cesk Psychiatr; 1982 Feb; 78(1):49-55. PubMed ID: 7060182
    [No Abstract]   [Full Text] [Related]  

  • 46. [Clinical significance of depot fluphenazine decanoate in therapy of acute psychotic disorders].
    Ngui PW
    Seishin Shinkeigaku Zasshi; 1983; 85(9):635-9. PubMed ID: 6676769
    [No Abstract]   [Full Text] [Related]  

  • 47. [Management of psychotic drive disorders].
    Langner E
    Wien Med Wochenschr; 1968 Sep; 118(36):700-2. PubMed ID: 5679053
    [No Abstract]   [Full Text] [Related]  

  • 48. The prolonged action of fluphenazine enanthate in oil after depot injection.
    Laffan RJ; High JP; Burke JC
    Int J Neuropsychiatry; 1965 Aug; 1(4):300-6. PubMed ID: 5863505
    [No Abstract]   [Full Text] [Related]  

  • 49. [Influence of endogenous hyperprolactinemia induced with administration of fluphenazine decanoate on urinary excretion of sodium and potassium].
    Spallone L; Camagna A; Magnatta R; Reda G; Dotti A; Lauro R
    Clin Ter; 1980 Feb; 92(4):389-97. PubMed ID: 7449318
    [No Abstract]   [Full Text] [Related]  

  • 50. [Circadian behavior of plasma testosterone and gonadotropins during hyperprolactinemia induced by administration of fluphenazine decanoate].
    Magnatta R; Spallone L; Camagna A; Reda G; Bersani G; Dotti A; Lauro R
    Clin Ter; 1980 Mar; 92(5):469-75. PubMed ID: 7449324
    [No Abstract]   [Full Text] [Related]  

  • 51. [Is it possible to envisage the treatment of various potentially dangerous states with prolonged-action chemotherapy?].
    Boissenin JM; Staël P; Poiré R
    Ann Med Psychol (Paris); 1970 May; 128(5):776-81. PubMed ID: 5452656
    [No Abstract]   [Full Text] [Related]  

  • 52. [Electroencephalographic study of fluphenazine].
    Borenstein P; Cujo P; Olivenstein C; Signarbieux S
    Ann Med Psychol (Paris); 1967 Apr; 125(4):586-94. PubMed ID: 6049289
    [No Abstract]   [Full Text] [Related]  

  • 53. Lithium augmentation fails to reduce symptoms in poorly responsive schizophrenic outpatients.
    Schulz SC; Thompson PA; Jacobs M; Ninan PT; Robinson D; Weiden PJ; Yadalam K; Glick ID; Odbert CL
    J Clin Psychiatry; 1999 Jun; 60(6):366-72. PubMed ID: 10401914
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Results of treatment by Moditen Depot in outpatients' wards in the South Moravian Region (author's transl)].
    Rektor L; Blazek J
    Cesk Psychiatr; 1980; 76(6):369-75. PubMed ID: 7471277
    [No Abstract]   [Full Text] [Related]  

  • 55. Serum neuroleptic levels during reduced dose fluphenazine decanoate maintenance therapy.
    Heresco-Levy U; Greenberg D; Lerer B; Javitt DC; Brown WA
    Isr J Psychiatry Relat Sci; 1997; 34(4):281-9. PubMed ID: 9409085
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A double-blind, controlled clinical trial of haloperidol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia.
    Chouinard G; Annable L; Campbell W; Boisvert D; Bradwejn J
    Psychopharmacol Bull; 1984; 20(1):108-9. PubMed ID: 6371871
    [No Abstract]   [Full Text] [Related]  

  • 57. Private ambulatory patients treated with fluphenazine enanthate.
    Kline NS; Simpson GM; Swenson JE
    Dis Nerv Syst; 1970 Sep; 31():Suppl:43-5. PubMed ID: 5476357
    [No Abstract]   [Full Text] [Related]  

  • 58. [Investigations on the psychological effects of fluphenazine in chronic psychoses].
    Sutter JM; Debrie ML; Scotto JC
    Ann Med Psychol (Paris); 1966 Jun; 124(1):19-33. PubMed ID: 5941449
    [No Abstract]   [Full Text] [Related]  

  • 59. Consequences of market withdrawal of fluphenazine and trifluoperazine: Letter to the editor and case series.
    Zanker J; Ferraro A
    Aust N Z J Psychiatry; 2017 Dec; 51(12):1256. PubMed ID: 28891312
    [No Abstract]   [Full Text] [Related]  

  • 60. [Against: is monotherapy the gold standard of psychopharmacology?].
    Bechter K
    Psychiatr Prax; 2006 Jul; 33(5):208-10. PubMed ID: 16874937
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.